Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Alligator Bioscience Starts Clinical Phase I Study With ATOR-1015 | ||||
By: PR Newswire Association LLC. - 11 Dec 2018 | Back to overview list |
|||
LUND, Sweden, Dec. 11, 2018 /PRNewswire/ -- Alligator Bioscience AB (Nasdaq Stockholm: ATORX) today announces that regulatory approvals have been obtained for the first clinical study of ATOR-1015 and patient recruitment can now be initiated. ATOR-1015 is a wholly-owned drug candidate developed for tumor-directed immunotherapy. The phase I study is a first-in-human dose-escalation study in up to 53 patients with advanced solid tumor disease at five different clinics across Sweden and Denmark. The primary aim of the study will be to investigate the safety and tolerability of the drug and to identify the recommended dose for subsequent Phase II studies. "The start of clinical phase I study with ATOR-1015 represents a significant milestone for Alligator. We are first in the world with a new concept, a tumor-localizing bispecific CTLA-4 antibody. While the target is clinically validated, the clinical use of CTLA-4 blocking agents is restricted by severe toxicity. ATOR-1015 may provide a solution through its potential for selective activation of the immune system in the tumor area but not elsewhere in the body. The drug's preclinical results are very promising, clearly supporting this concept", said Per Norlén, CEO of Alligator Bioscience. As previously communicated, Alligator has appointed Theradex Oncology, a global contract research organization with extensive expertise in oncology clinical development, to conduct the phase I study. For further information, please contact: This information is such information as Alligator Bioscience AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8:00 a.m. CET on December 11, 2018. About ATOR-1015 About Alligator Bioscience This information was brought to you by Cision http://news.cision.com The following files are available for download:
View original content:http://www.prnewswire.com/news-releases/alligator-bioscience-starts-clinical-phase-i-study-with-ator-1015-300763190.html SOURCE Alligator Bioscience |
||||
|
||||
Copyright 2018 PR Newswire Association LLC. | Back to overview list |